Charles Schwab’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-101,876
| Closed | -$2.21M | – | 3120 |
|
|
2017
Q2 | $2.21M | Buy |
101,876
+589
| +0.6% | +$10.7K | ﹤0.01% | 2191 |
|
|
2017
Q1 | $1.42M | Buy |
101,287
+5,301
| +6% | +$86.8K | ﹤0.01% | 2310 |
|
|
2016
Q4 | $1.8M | Buy |
95,986
+4,774
| +5% | +$81.2K | ﹤0.01% | 2222 |
|
|
2016
Q3 | $1.51M | Buy |
91,212
+41,812
| +85% | +$619K | ﹤0.01% | 2265 |
|
|
2016
Q2 | $664K | Hold |
49,400
| – | – | ﹤0.01% | 2492 |
|
|
2016
Q1 | $756K | Hold |
49,400
| – | – | ﹤0.01% | 2433 |
|
|
2015
Q4 | $981K | Hold |
49,400
| – | – | ﹤0.01% | 2395 |
|
|
2015
Q3 | $861K | Hold |
49,400
| – | – | ﹤0.01% | 2438 |
|
|
2015
Q2 | $999K | Buy |
49,400
+7,400
| +18% | +$143K | ﹤0.01% | 2421 |
|
|
2015
Q1 | $740K | Hold |
42,000
| – | – | ﹤0.01% | 2493 |
|
|
2014
Q4 | $684K | Hold |
42,000
| – | – | ﹤0.01% | 2513 |
|
|
2014
Q3 | $927K | Sell |
42,000
-17,320
| -29% | -$355K | ﹤0.01% | 2334 |
|
|
2014
Q2 | $1.19M | Sell |
59,320
-61,700
| -51% | -$1.05M | ﹤0.01% | 2241 |
|
|
2014
Q1 | $2.25M | Buy |
121,020
+67,020
| +124% | +$923K | ﹤0.01% | 1884 |
|
|
2013
Q4 | $545K | Sell |
54,000
-42,000
| -44% | -$508K | ﹤0.01% | 2560 |
|
|
2013
Q3 | $1.25M | Sell |
96,000
-54,200
| -36% | -$667K | ﹤0.01% | 2109 |
|
|
2013
Q2 | $1.91M | Buy |
+150,200
| New | +$1.63M | ﹤0.01% | 1789 |
|
Other funds holding AMRI
Charles Schwab's AMRI Position: Q3 2017 in Review
Charles Schwab sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 101,876 shares — an estimated $2.21M sold.
Charles Schwab first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $2.25M in Q1 2014. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Charles Schwab reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Charles Schwab sold 101,876 Albany Molecular Research Inc shares in Q3 2017, an estimated $2.21M.
- Charles Schwab first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- Charles Schwab's Albany Molecular Research Inc position peaked at $2.25M in Q1 2014.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Charles Schwab's 13F filing for Q3 2017, filed 13 Nov 2017.